Peripheral Neuritis Treatment Market Size

Peripheral Neuritis Treatment Market size was valued at USD 1.87 Billion in 2023 and is likely to cross USD 3.03 Billion by the end of 2036, registering more than 3.8% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of peripheral neuritis treatment is estimated at USD 1.93 Billion. The growth of the market can primarily be attributed to the prevalence of deaths due to chronic diseases such as cancer and thyroid as well as other chronic diseases worldwide. According to the American Cancer Society, approximately 2,230 people died from thyroid cancer in the United States in 2022, and 43,800 people were diagnosed with thyroid cancer.

An unhealthy lifestyle has resulted in many chronic diseases among the population. One of them is cancer, which is treated as the main cause of peripheral neuritis due to chemotherapy in cancer patients. Thus, the large number of cancer deaths worldwide is expected to create massive revenue generation opportunities for the key players operating.

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of peripheral neuritis treatment is estimated at USD 1.93 Billion.

The peripheral neuritis treatment market size was valued at USD 1.87 Billion in 2023 and is likely to cross USD 3.03 Billion by the end of 2036, registering more than 3.8% CAGR during the forecast period i.e., between 2024-2036. The rising chronic diseases globally, and the large aging population are some of the major factors anticipated to drive the growth of the market.

North America industry is expected to account for majority revenue share by 2036, backed by presence of a large pool of diabetic patients and a burgeoning aging population in the region.

Eli Lilly and Company, Abbott, Bristol Myers Squibb Company, Novartis AG, Pfizer Inc., GSK Group of Companies, Merck & Co., Inc., F. Hoffmann-La Roche Ltd, RxFunction, Inc., Cipla Limited

Peripheral Neuritis Treatment Market Size